Previous 10 | Next 10 |
THE WOODLANDS, Texas, July 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has changed the date of its previously announced earnings release, conference call and webcast and will now release financial results for the second quarter of 2...
Gainers: NovaBay Pharmaceuticals (NYSEMKT: NBY ) +34% . Medley Management (NYSE: MDLY ) +33% . Pieris Pharmaceuticals (NASDAQ: PIRS ) +24% . Daxor (NYSEMKT: DXR ) +18% . Oasmia Pharmaceutical AB (NASDAQ: OASM ) +17% . Acasti Pharma (NASDAQ: ACST ) +15% . Mylan N.V. (NASDAQ: MYL...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) -54% . More news on: Lexicon Pharmaceuticals, Inc., Obalon Therapeutics, Inc., Exact Sciences Corporation, Stocks on the move, Read more ...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
Lexicon Pharmaceuticals ’ ( LXRX ) tortuous path to success in the diabetes market took another big hit late on Friday July 26, when Sanofi ( SNY ) issued a press release containing a brief summation of top-line results of three Phase III Type 2 diabetes studies of Zynquista and no...
THE WOODLANDS, Texas,, July 26, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), received preliminary topline results from Sanofi for three Phase 3 trials of Zynquista™ (sotagliflozin) in adults living with type 2 diabetes from the InSynchrony clinical ...
After mixed results in two Phase 3 studies, Sanofi (NASDAQ: SNY ) has decided to terminate its collaboration with Lexicon Pharmaceuticals (NASDAQ: LXRX ) to develop, manufacture and commercialize Zynquista (sotagliflozin) for controlling blood sugar levels in type 1 and 2 diabetics. More...
THE WOODLANDS, Texas, July 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2019 financial results on Thursday, August 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a...
THE WOODLANDS, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of clinical data for sotagliflozin will be presented at the upcoming 79 th American Diabetes Association (ADA) Scientific Sessions in San Francisco, Califo...
The FDA approves AstraZeneca's (NYSE: AZN ) Qternment XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended-release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D). More news on: AstraZeneca PLC, E...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA ® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related ...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced its participation in the Bank...
THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentati...